he ticket to CavinKare's stardom was the humble sachet. When its founder Chinni Krishnan Ranganathan started selling shampoo for 50 paise in sachets in 1983, it did create a stir in a market where biggies such as Hindustan Unilever and Procter and Gamble (P&G) had ruled the roost for decades.
With that one innovation, the hitherto non-existent rural market was well within Ranganathan's grasp. As brand consultant Harish Bijoor puts it, "It democratised shampoo usage."
Building on that, by the early years of 2000, Chennai-based CavinKare (named after the classical Tamil word for beauty) and known for its Chik shampoo managed to come across as a doughty challenger to the big guys of the FMCG industry. It had started getting termed "the giant killer". By 2004-05, when CavinKare was about Rs 400 crore in revenue, the momentum was so good that Ranganathan predicted joining the billion-dollar club by 2012.
Billion Never Happened
Eight years later, it is clear the company hasn't lived up to its promise. CavinKare has just managed a fifth of what Ranganathan had predicted: Rs 1,070 crore in revenues. A recent PINC Research study gives details. In skin care, a money spinner for fast-moving consumer goods (FMCG) companies, CavinKare has just about a 5% market share.
HUL has a whopping 58% of the market while L'Oreal, P&G and Emami have a 13%, 10% and 9% market share, respectively. In the shampoo market, CavinKare may have a better record, with a 11% market share, but still lags the likes of HUL, P&G and Dabur. As Nikhil Vora, managing director of IDFC Securities, puts it, "They have taken a backseat. They are no longer challenging the leader."
What Went Wrong?
You can get the answer by comparing Ranganathan's business interests a decade back and now. Then, he was essentially building a base in the FMCG sector. In fact, in 2002, his talcum powder foray itself was just three years old. Now, his interests go beyond FMCG. In the past 10 years, he has forayed into salons, into food, into beverages, into home care, into snacks, into restaurants and into dairy.
New businesses in themselves aren't bad. But, critics point out, they have come at the cost of the core FMCG business. "They were aggressive in entering new spaces but weren't growing their existing business," says Vora. Ranganthan may have lost the opportunity of scaling up his core business as he had to spend management bandwidth and money on newer interests. And, diversifications such as food and beverages won't work without big marketing spends.
Losing Its Core
One of the key fallouts of the defrayed focus is seen as CavinKare's inability to read the market in certain instances in its core business. Take the example of shampoo. While the market was moving toward anti-dandruff shampoo, it didn't. Today, a fourth of the market is anti-dandruff shampoo.
Also, Vora says, "The market was moving towards premium brands and CavinKare was at the bottom end." Bijoor agrees: "The brand still suffers the mindset of a down-market player."
Also, MNCs, whom CavinKare is competing against, have deep pockets for R&D. So, there's virtually a pipeline of new products and innovations at all times. A smaller player over time needs to match that. For CavinKare, innovations such as sachet may have become far and few. Also, to do it in multiple businesses is a bit too much for a medium-sized player.
'We Will Grow'
Ranganathan does agree to the criticism that his company has spread itself quite thin. "Having taken those steps, we can't reverse it. We will not take any more step in diversification. We will only look at consolidating and growing," he says.
Ranganathan the person is actually quite like Ranganathan the businessman on the point of wide-ranging interests. He is interested in the Tamil language and loves birds (he has 200 different species of birds). What more, he has even modelled for a shirt brand.
In business, however, his wide-ranging interests haven't paid off till now, he admits. "We don't leverage the advantage of one division to another," he says. That's especially true of his food, beverages, snacks and dairy businesses. "If all the products get into the same distribution line, then I can leverage."
Ranganathan gives the example of his foray into dairy four years back. It was a market that was completely different from what he had experienced earlier. That included everything from the highly perishable nature of the product, the cold process distribution, the profile of people who were willing to invest and also the systems and processes to be used. "So I don't leverage anything here," he says.
New Revenue Hopes
Diversifications done, lessons learnt, the CavinKare chief believes growth will follow now. His hope is that his group would double its revenues in two years. Those who have tracked the company believe some positive moves have been taken of late. Raveendra Chittoor, a strategy expert who teaches at the Indian School of Business, Hyderabad, says the move to go slow on the restaurant business is one such.
Also, Ranganathan also moved his marketing team to Mumbai from Chennai last year. One reason is to effect a pan-India presence, something that CavinKare has struggled with until now. That's a pragmatic move, says ad veteran Suguna Swamy. "This move reflects the realism of the man. If he has to go national, he needs to be located in Mumbai, both for resources and bandwidth of talent," she says.
Ultimately, focus, Chittoor believes, is inevitable. "It should focus on a few product categories in which it has a competitive edge and try and achieve national leadership in those." That's the lesson one can learn from successful companies such as Marico, says Chittoor. That could be key to its future.
"Believer - Humanitarian - Habit of Success" Sukumar Balakrishnan is the Founder of JB GROUP, a 500 Crore National Organization with over 150 Direct & 1200 indirect professionals operating from 5 major cities in India. Jayalakshmi Balakrishnan Group, a multi-faceted group venturing into, E- Commerce and Import-Export (INNOKAIZ), Retail and Wholesale (JB MART), Food and Beverages (KRISHNA FOODS ), Real Estate (Constructions on sites, Interior scaping, Facility Management)
Total Pageviews
Monday, May 7, 2012
ajaj Pulsar crosses 50 lakh sales mark since its launch
NEW DELHI: The country's second largest two-wheeler maker Bajaj Auto today said its Pulsar model motorcycles have crossed 50 lakh units sales mark since its launch over 10 years ago.
"The (Pulsar) brand has crossed the landmark 5 million sales mark, while celebrating a decade of existence. Pulsar is the only brand in the performance segment which has crossed the 5 million mark in India," Bajaj Auto Ltd (BAL) said in a statement.
The company had first introduced the Pulsar motorcycles in November 2001 in two engine capacities -- 180 cc and 150 cc, it added.
The brand today has a portfolio starting from 135 cc light-sports model to 220 cc 'street-fighter' product and enjoys a market share of 44 per cent in the performance segment, BAL claimed.
"Not many brands in the Indian automobile space have crossed the 5 million mark. This holds true even for mass motorcycles. The Pulsar range has received many accolades over the years," BAL President (Motorcycle Business) K Srinivas said.
The company had unveiled the Pulsar 200 NS early this year and it is hopeful of the model doing good in the market, he added.
"The (Pulsar) brand has crossed the landmark 5 million sales mark, while celebrating a decade of existence. Pulsar is the only brand in the performance segment which has crossed the 5 million mark in India," Bajaj Auto Ltd (BAL) said in a statement.
The company had first introduced the Pulsar motorcycles in November 2001 in two engine capacities -- 180 cc and 150 cc, it added.
The brand today has a portfolio starting from 135 cc light-sports model to 220 cc 'street-fighter' product and enjoys a market share of 44 per cent in the performance segment, BAL claimed.
"Not many brands in the Indian automobile space have crossed the 5 million mark. This holds true even for mass motorcycles. The Pulsar range has received many accolades over the years," BAL President (Motorcycle Business) K Srinivas said.
The company had unveiled the Pulsar 200 NS early this year and it is hopeful of the model doing good in the market, he added.
Bio-diversity museum to be set up in Hyderabad
Hyderabad: With the mega global biodiversity meet in October approaching, the Andhra Pradesh Government has set in motion a series of initiatives, both preparatory and commemorative.
The Government plans to establish a museum on bio-diversity to commemorate the global Convention on Biodiversity (CBD). Similarly, it wants to put up a pylon and develop a bio-diversity park ahead of the Conference of Parties (CoP-11).
The mega event will see about 8,000 delegates from 193 countries take part. About 10 heads of nations, apart from forest ministers of 90-100 countries will deliberate on various issues.
The State Chief Minister, Mr Kiran Kumar Reddy, who reviewed a preparatory meeting, said the bio-diversity park should be established at a suitable location, preferably in Dulapally reserve forest area on the outskirts of Hyderabad.
The objective of these initiatives is to create awareness among the people, especially students and children, about the rich biological heritage and importance of conservation.
The Government plans to establish a museum on bio-diversity to commemorate the global Convention on Biodiversity (CBD). Similarly, it wants to put up a pylon and develop a bio-diversity park ahead of the Conference of Parties (CoP-11).
The mega event will see about 8,000 delegates from 193 countries take part. About 10 heads of nations, apart from forest ministers of 90-100 countries will deliberate on various issues.
The State Chief Minister, Mr Kiran Kumar Reddy, who reviewed a preparatory meeting, said the bio-diversity park should be established at a suitable location, preferably in Dulapally reserve forest area on the outskirts of Hyderabad.
The objective of these initiatives is to create awareness among the people, especially students and children, about the rich biological heritage and importance of conservation.
SlideShare success an inspiration for Indian developers
Bangalore/New Delhi: The SlideShare engine, which helps users upload presentations online and embed these on blog, websites, intranets and social media, was mostly developed by the company’s Indian developers. The company that was recently acquired by online professional networking company LinkedIn for a handsome $119 million (about Rs 640 crore) has majority of its developers and designers in New Delhi.
The person behind the successful business venture, which she co-founded with her husband Jonathan Boutelle and brother Amit Ranjan, however, is not a techie, going by her academic qualifications. Rashmi Sinha, who was born and educated in Allahabad before going for a PhD at Brown University, studied psychology.
"What Rashmi and Amit have achieved is truly commendable. They'll be an inspiration to many entrepreneurs in India. Our software product ecosystem is becoming strongly by the day," says Sharad Sharma, chairman of Nasscom Product Forum and the former chief executive of Yahoo! India R&D centre.
While Ranjan heads the company’s office in New Delhi, the core technology development work is being taken care of by Kapil Mohan, technical architect who has been working with the company since its inception.
Before SlideShare, Rashmi also co-founded two other ventures including Uzanto, a web consulting company and MindCanvas a gaming product company.
“When I was at Brown University, it felt too isolated, too ivory tower. When I discovered the Web, and how you could build for it and constantly iterate, it seemed a far more exciting prospect than sitting in a lab doing made-up experiments on people,” she had written in one of her blogposts.
In her latest blogpost, while disclosing SlideShare was being acquired by LinkedIn, Rashmi has stated she would continue to lead SlideShare and her team would continue to do what they had been doing.
Smartphone shipments to reach 1.7 billion
New Delhi/ Melbourne: Smartphones will outperform the overall market for mobile phones, growing at a compound annual growth rate (CAGR) of 24.9% for the period 2011-17 to reach 1.7 billion units, according to Ovum.
Predictions show Android as the dominant operating system over the next five years as handset vendors rush to make it their primary smartphone platform. In its latest forecast, Mobile Phone and Smartphone Forecast: 2012-17, the leading telecoms analyst house reveals global annual mobile phone shipments will grow at a CAGR of 6.3% between 2011 and 2017, driven primarily by demand from emerging markets where connection growth will continue to fuel handset shipments.
Asia-Pacific will be the largest region in volume terms, shipping just over 200 million units by 2016. New shipments in developed markets, such as North America and Western Europe, will be almost entirely made up of smartphones, while feature phones will continue to play a small role in emerging markets in 2017. "Android will dominate the smartphone market over the next five years," said Adam Leach, principal analyst at Ovum. "While Apple has defined the smartphone market since it introduced the iPhone in 2007, we're now seeing a sharp rise in the shipment volumes of Android, signaling its appeal to leading handset manufacturers."
Smartphones based on Android accounted for 44% of the smartphone market in 2011, significantly up from 17% in 2010. However, its share will reach 48% in 2017, as Android-based smartphones are expected to grow at a CAGR of 26.8% over the forecast period. Apple's iOS will be the second most widely deployed software platform in 2017, accounting for 27% of the smartphone market, a slight increase on the 23% share of the market it reported in 2011. Sitting some way behind the Android/iOS duopoly will be the remaining smartphone players.
"Although it will remain behind Android in terms of shipment volumes, Apple will continue to be a key player and innovator in the smartphone market over the forecast period," says Leach. "We expect Microsoft, despite its slow start, to have established Windows Phone as a relevant smartphone platform by 2017." The Windows Phone platform, with the assistance of Nokia, will account for 13% of the smartphone market in 2017. Despite losing significant market share since its high point in 2009, RIM's BlackBerry platform will still represent 10% of the market in 2017.
Predictions show Android as the dominant operating system over the next five years as handset vendors rush to make it their primary smartphone platform. In its latest forecast, Mobile Phone and Smartphone Forecast: 2012-17, the leading telecoms analyst house reveals global annual mobile phone shipments will grow at a CAGR of 6.3% between 2011 and 2017, driven primarily by demand from emerging markets where connection growth will continue to fuel handset shipments.
Asia-Pacific will be the largest region in volume terms, shipping just over 200 million units by 2016. New shipments in developed markets, such as North America and Western Europe, will be almost entirely made up of smartphones, while feature phones will continue to play a small role in emerging markets in 2017. "Android will dominate the smartphone market over the next five years," said Adam Leach, principal analyst at Ovum. "While Apple has defined the smartphone market since it introduced the iPhone in 2007, we're now seeing a sharp rise in the shipment volumes of Android, signaling its appeal to leading handset manufacturers."
Smartphones based on Android accounted for 44% of the smartphone market in 2011, significantly up from 17% in 2010. However, its share will reach 48% in 2017, as Android-based smartphones are expected to grow at a CAGR of 26.8% over the forecast period. Apple's iOS will be the second most widely deployed software platform in 2017, accounting for 27% of the smartphone market, a slight increase on the 23% share of the market it reported in 2011. Sitting some way behind the Android/iOS duopoly will be the remaining smartphone players.
"Although it will remain behind Android in terms of shipment volumes, Apple will continue to be a key player and innovator in the smartphone market over the forecast period," says Leach. "We expect Microsoft, despite its slow start, to have established Windows Phone as a relevant smartphone platform by 2017." The Windows Phone platform, with the assistance of Nokia, will account for 13% of the smartphone market in 2017. Despite losing significant market share since its high point in 2009, RIM's BlackBerry platform will still represent 10% of the market in 2017.
Kerala Tourism road show in Saudi Arabia
Thiruvananthapuram: Kerala Tourism is holding its maiden road show in Jeddah, the thriving urban centre of oil-rich Saudi Arabia from Sunday. The three-day event will travel to capital Riyadh and Dammam on Monday and the day after.
The Tourism Minister, Mr A.P. Anil Kumar, will lead the road shows, a Kerala Tourism spokesman announced here. These are being held at a time when the middle-east is emerging as a major market for the world's exotic destinations.
“Saudi Arabia is the biggest market for outbound tourists in the region,” the spokesman quoted the Minister as saying. “We want to invite travellers from Saudi Arabia to Kerala's world renowned tourism destinations,” he added.
High-Spending
Saudi Arabian tourists are the highest spending travellers abroad from the Middle-East. Nearly half of the country's population falls in the higher income bracket.
Saudi Arabians look for holidays in the harsh summer (June to September) in their country when temperatures hover above 50 degree Celsius.
Kerala's monsoon tourism and Ayurveda are already drawing a number of travellers from Saudi Arabia, the spokesman said. Health and wellness holidays are a major segment of outbound travel from Saudi Arabia, a factor Kerala Tourism is keen to leverage in its favour.
Outbound Tourists
The country's proximity to Kerala and good air connectivity are the other factors in favour of God's Own Country.
The Middle-East has recorded more than nine million outbound tourists in 2011 and the figure is likely to touch 35 million by 2020.
Saudi Arabia accounts for 40 per cent of these, he added. Others now joining the list include United Arab Emirates, Qatar, Oman, Kuwait and Bahrain.
Around 50 local tour operators are expected to participate in the road shows in each of the three Saudi Arabian cities.
The Tourism Minister, Mr A.P. Anil Kumar, will lead the road shows, a Kerala Tourism spokesman announced here. These are being held at a time when the middle-east is emerging as a major market for the world's exotic destinations.
“Saudi Arabia is the biggest market for outbound tourists in the region,” the spokesman quoted the Minister as saying. “We want to invite travellers from Saudi Arabia to Kerala's world renowned tourism destinations,” he added.
High-Spending
Saudi Arabian tourists are the highest spending travellers abroad from the Middle-East. Nearly half of the country's population falls in the higher income bracket.
Saudi Arabians look for holidays in the harsh summer (June to September) in their country when temperatures hover above 50 degree Celsius.
Kerala's monsoon tourism and Ayurveda are already drawing a number of travellers from Saudi Arabia, the spokesman said. Health and wellness holidays are a major segment of outbound travel from Saudi Arabia, a factor Kerala Tourism is keen to leverage in its favour.
Outbound Tourists
The country's proximity to Kerala and good air connectivity are the other factors in favour of God's Own Country.
The Middle-East has recorded more than nine million outbound tourists in 2011 and the figure is likely to touch 35 million by 2020.
Saudi Arabia accounts for 40 per cent of these, he added. Others now joining the list include United Arab Emirates, Qatar, Oman, Kuwait and Bahrain.
Around 50 local tour operators are expected to participate in the road shows in each of the three Saudi Arabian cities.
Japan's imports from India up 21.5% in last fiscal
Kolkata: Japan's imports from India jumped 21.5 per cent to ¥54 billion in the financial year that ended on March 31. Mr Mitsuo Kawaguchi, Consul General of Japan, said this at an interaction with EEPC India (formerly Engineering Export Promotion Council) members here.
The Indian engineering industry appears poised for better access to the Japanese market and more Japanese companies are willing to set up joint ventures with their Indian counterparts. Mr Kawaguchi said after the signing of the Comprehensive Economic Partnership Agreement (CEPA) in February last year that there has been a visible change in the two-way trade.
Under the CEPA, Japan eliminated tariffs on 87 per cent of its tariff lines. Over the next decade, it would remove import tariffs in a phased manner on nearly 97 per cent of the tariff lines. Iron, steel, zinc, aluminium and copper items from India can pass through with zero duty into Japan.
Industrial and automotive components form a substantial part of the exports to Japan.
“Japan is looking for outsourcing opportunity in India,” he said. Japanese companies are also keen to set up manufacturing bases in India.
The Indian engineering industry appears poised for better access to the Japanese market and more Japanese companies are willing to set up joint ventures with their Indian counterparts. Mr Kawaguchi said after the signing of the Comprehensive Economic Partnership Agreement (CEPA) in February last year that there has been a visible change in the two-way trade.
Under the CEPA, Japan eliminated tariffs on 87 per cent of its tariff lines. Over the next decade, it would remove import tariffs in a phased manner on nearly 97 per cent of the tariff lines. Iron, steel, zinc, aluminium and copper items from India can pass through with zero duty into Japan.
Industrial and automotive components form a substantial part of the exports to Japan.
“Japan is looking for outsourcing opportunity in India,” he said. Japanese companies are also keen to set up manufacturing bases in India.
Sunday, May 6, 2012
Narayana Hrudayalaya plans Rs 5,000-cr expansion in 5 years
Ahmedabad: The Bangalore-based Narayana Hrudayalaya Hospitals (NH), which currently has 14 hospitals with 6,000 beds across seven States, is planning to invest nearly Rs 5,000 crore on setting up a chain of 100 low-cost specialty hospitals and at least three more health cities in the country.
The low-cost hospitals will add about 30,000 beds in five years. The company will invest Rs 25-30 crore on each of these hospitals using pre-fabricated construction materials.
“The first such hospital is being built by L&T in Mysore. We want to prove that such a modern , 300-bed multispecialty hospital can be built for $6-7 million (Rs 35 crore) as against the estimates of $25 million,” Dr Devi Shetty, Chairman, said here on Thursday.
These hospitals will be opened in about 100 Indian cities having population of between five and 10 lakhs. Nine such projects will be operational in the next 18 months
After Bangalore, the company's second super-specialty Health City complex, offering all healthcare facilities at one place, is coming up in a 37-acre area of Ahmedabad.
Total investment
With a total investment of Rs 600 crore planned in five years, it will have 5,000 beds in three-four phases, besides a medical college that will admit 200 students from poor families, nursing and paramedical institutions.
In the first phase, inaugurated on Thursday by the Gujarat Chief Minister, Mr Narendra Modi, NH has provided 300 beds at a cost of Rs 110 crore.
“Economy of scale, sharing infrastructure and expertise reduces our cost of operation and other expenses,” said Dr Shetty.
About half-a-dozen more hospitals will be established in the same campus, Dr A. Raghuvanshi, Managing Director, told Business Line. “We are also planning to set up two more health cities, in West Bengal and Uttar Pradesh, at similar investments.”
Dr Shetty said India needs to perform 25 lakh heart operations annually but is able to operate only about 90,000 patients.
“We want to make India the first nation to dissociate healthcare from prosperity by providing ultramodern treatment at the lowest cost.”
The low-cost hospitals will add about 30,000 beds in five years. The company will invest Rs 25-30 crore on each of these hospitals using pre-fabricated construction materials.
“The first such hospital is being built by L&T in Mysore. We want to prove that such a modern , 300-bed multispecialty hospital can be built for $6-7 million (Rs 35 crore) as against the estimates of $25 million,” Dr Devi Shetty, Chairman, said here on Thursday.
These hospitals will be opened in about 100 Indian cities having population of between five and 10 lakhs. Nine such projects will be operational in the next 18 months
After Bangalore, the company's second super-specialty Health City complex, offering all healthcare facilities at one place, is coming up in a 37-acre area of Ahmedabad.
Total investment
With a total investment of Rs 600 crore planned in five years, it will have 5,000 beds in three-four phases, besides a medical college that will admit 200 students from poor families, nursing and paramedical institutions.
In the first phase, inaugurated on Thursday by the Gujarat Chief Minister, Mr Narendra Modi, NH has provided 300 beds at a cost of Rs 110 crore.
“Economy of scale, sharing infrastructure and expertise reduces our cost of operation and other expenses,” said Dr Shetty.
About half-a-dozen more hospitals will be established in the same campus, Dr A. Raghuvanshi, Managing Director, told Business Line. “We are also planning to set up two more health cities, in West Bengal and Uttar Pradesh, at similar investments.”
Dr Shetty said India needs to perform 25 lakh heart operations annually but is able to operate only about 90,000 patients.
“We want to make India the first nation to dissociate healthcare from prosperity by providing ultramodern treatment at the lowest cost.”
Indian pharma companies like Hetero, Alembic, Lupin, Dr Reddy's dominating US generic space
Mumbai: India is playing a dominant role in the US generic pharma space, having cornered over half the certified dossiers filed globally for active pharmaceutical ingredients (API). Drug companies from India filed 51% of the overall global applications, also called drug master filings (DMF), in the US market during calendar year 2011. DMFs are essentially approvals to supply complex raw materials to all generic manufacturers servicing the US market, which is the most lucrative of all global markets.
Over the last three years, there has been a sustained increase in the trend of such applications from India. Of the global DMF filings in the US, India accounted for 45% in 2009, which increased to 49% in 2010 and 51% in 2011 (see chart).
Against this, China which is the leading API supplier in emerging markets, cornered only 18% of the total DMFs filed in the US in 2011, down from 20% in 2010. Interestingly, midrung companies like Hetero, and even smaller ones like USV, Nectar Life Sciences, Shilpa Medicare and Gland Pharma are now filing for such approvals from the US Food and Drug Administration.
Says Glenn Saldanha, chairman and MD, Glenmark Pharma, "Indian companies are playing a huge role in providing tangible, long-term value to generic players in the US market. US being the largest standalone generic market, continues to offer attractive partnership opportunities as most US dosage manufacturers (barring the top four or five) are not backward integrated."
Among the companies, Hyderabad-based Hetero had the maximum new filings at eight during the fourth quarter of 2011.Others like Alembic, Emcure and Gland have filed four DMFs each. Among large players, Lupin and Dr Reddy's filed three each, while Sun Pharma had two filings, and Cadila filed for one. Other significant filers were Jubilant, Aurobindo, Ipca (two each), while Orchid and Torrent filed for one each.
It was the first time that domestic players filed for 22 molecules during the quarter (higher than eight in 3Q11), of which the Prasugrel filing by Dr Reddy's may lead to a new chemical entity, according to a JM Financial analyst.
Says Sujay Shetty, partner, PwC India, "Domestic companies have moved up the value curve by filing complex certified dossiers. These filings are important for domestic as well as US companies, which are filing for approvals to launch generic drugs (abbreviated new drug application), and are truly indicative of the quality and regulatory compliance, which has become critical. Also, for Indian manufacturers in the US, sourcing APIs from Indian companies, lowers costs." Sales of APIs in the US have also started augmenting US revenues of these Indian companies .
In the past, industry experts say domestic companies targeted less-regulated markets for API and this space is now extremely competitive. So, many of them decided to make the transition of supplying APIs to regulated markets. And to do this they naturally had to build on their R&D capabilities to meet the stringent requirements of countries like the US.
"Basically, two aspects have emerged... Not only are Indian companies offering standalone APIs but are also increasingly offering finished dosages as part of vertically integrated partnership deals. This is most true for mid-rung players which presently do not have a direct presence in the US market ," adds Saldanha.
Over the last three years, there has been a sustained increase in the trend of such applications from India. Of the global DMF filings in the US, India accounted for 45% in 2009, which increased to 49% in 2010 and 51% in 2011 (see chart).
Against this, China which is the leading API supplier in emerging markets, cornered only 18% of the total DMFs filed in the US in 2011, down from 20% in 2010. Interestingly, midrung companies like Hetero, and even smaller ones like USV, Nectar Life Sciences, Shilpa Medicare and Gland Pharma are now filing for such approvals from the US Food and Drug Administration.
Says Glenn Saldanha, chairman and MD, Glenmark Pharma, "Indian companies are playing a huge role in providing tangible, long-term value to generic players in the US market. US being the largest standalone generic market, continues to offer attractive partnership opportunities as most US dosage manufacturers (barring the top four or five) are not backward integrated."
Among the companies, Hyderabad-based Hetero had the maximum new filings at eight during the fourth quarter of 2011.Others like Alembic, Emcure and Gland have filed four DMFs each. Among large players, Lupin and Dr Reddy's filed three each, while Sun Pharma had two filings, and Cadila filed for one. Other significant filers were Jubilant, Aurobindo, Ipca (two each), while Orchid and Torrent filed for one each.
It was the first time that domestic players filed for 22 molecules during the quarter (higher than eight in 3Q11), of which the Prasugrel filing by Dr Reddy's may lead to a new chemical entity, according to a JM Financial analyst.
Says Sujay Shetty, partner, PwC India, "Domestic companies have moved up the value curve by filing complex certified dossiers. These filings are important for domestic as well as US companies, which are filing for approvals to launch generic drugs (abbreviated new drug application), and are truly indicative of the quality and regulatory compliance, which has become critical. Also, for Indian manufacturers in the US, sourcing APIs from Indian companies, lowers costs." Sales of APIs in the US have also started augmenting US revenues of these Indian companies .
In the past, industry experts say domestic companies targeted less-regulated markets for API and this space is now extremely competitive. So, many of them decided to make the transition of supplying APIs to regulated markets. And to do this they naturally had to build on their R&D capabilities to meet the stringent requirements of countries like the US.
"Basically, two aspects have emerged... Not only are Indian companies offering standalone APIs but are also increasingly offering finished dosages as part of vertically integrated partnership deals. This is most true for mid-rung players which presently do not have a direct presence in the US market ," adds Saldanha.
Abbott Laboratories in pact with Biocon to develop nutrition products
Mumbai: Abbott Laboratories will collaborate with Bangalore-based Biocon to establish a research and development centre to develop nutrition products in India.
Abbott Nutrition Centre, India will work with Syngene, the contract research arm of Biocon, to develop affordable products for maternal, child nutrition and diabetes care, the companies said in a joint press release.
"We have consistently invested in India and this world-class research and development centre will allow us to leverage local expertise and insights to develop products we need to successfully expand our portfolio here," said Rehan Khan, managing director, Abbott Nutrition India.
Indian nutrition market is estimated to be about 1,500 crore, according to an estimate by Motilal Oswal. In the past three years, global foods companies have set eyes on the Indian nutrition market for its sheer size.
In 2011, French diary giant Danone had acquired nutrition business of India's Wockhardt Pharma for 1,500 crore, after an unsuccessful attempt by Abbott to buy the business. Currently, Abbott sells Pediasure, one of the oldest available nutrition products in India.
Abbott Nutrition Centre, India will work with Syngene, the contract research arm of Biocon, to develop affordable products for maternal, child nutrition and diabetes care, the companies said in a joint press release.
"We have consistently invested in India and this world-class research and development centre will allow us to leverage local expertise and insights to develop products we need to successfully expand our portfolio here," said Rehan Khan, managing director, Abbott Nutrition India.
Indian nutrition market is estimated to be about 1,500 crore, according to an estimate by Motilal Oswal. In the past three years, global foods companies have set eyes on the Indian nutrition market for its sheer size.
In 2011, French diary giant Danone had acquired nutrition business of India's Wockhardt Pharma for 1,500 crore, after an unsuccessful attempt by Abbott to buy the business. Currently, Abbott sells Pediasure, one of the oldest available nutrition products in India.
Subscribe to:
Posts (Atom)